Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (VERA) granted inducement equity awards on September 1, 2026 to six new employees under its 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 61,500 Class A shares at an exercise price of $34.23 per share and RSUs covering 30,750 Class A shares. Options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually over four years from either August 20 or November 20, 2026, depending on employee start date, subject to continued service.
Vera Therapeutics (Nasdaq: VERA) will participate in two investor conferences in New York. The company will host fireside chats and 1x1 investor meetings at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00am ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 5:35pm ET. Webcasts for both events will be accessible online, with replays available for 90 days via the News & Events section of Vera Therapeutics’ website.
Vera Therapeutics (Nasdaq: VERA) reported Q2 2026 results and a major regulatory milestone: the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression, and the U.S. launch is underway.
The approval was based on ORIGIN Phase 3 data showing a 46% proteinuria reduction from baseline and 42% versus placebo at 36 weeks, plus a 68% reduction in Gd-IgA1 and 81% hematuria resolution, with generally tolerable safety. Vera aligned with FDA on an earlier ORIGIN 3 final efficacy analysis, expected in Q3 2026, to support a potential full approval, with an sBLA planned for Q4 2026 and possible full approval in 2027.
For Q2 2026, Vera reported a net loss of $109.5 million ($1.52 per share) versus $76.5 million ($1.20 per share) a year earlier. Cash, cash equivalents and marketable securities totaled $499.2 million at June 30, 2026, with up to $425 million remaining available under its debt facility, subject to conditions.
Vera Therapeutics (Nasdaq: VERA) reported that its Board Compensation Committee granted Nasdaq Listing Rule 5635(c)(4) inducement equity awards under the 2024 Inducement Plan on August 3–4, 2026. The grants include non-qualified stock options for 63,011 shares and RSUs for 44,987 shares to new Chief Regulatory Officer Nancy Bowman, M.D., Ph.D., and options for 5,600 shares plus RSUs for 2,800 shares to two new employees.
Options granted on August 3 have an exercise price of $32.23 per share, and those granted on August 4 have a $29.95 exercise price. Options vest over four years with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually on each August 20 over four years, all subject to continued service and award agreements.
Vera Therapeutics (Nasdaq: VERA) reported that on July 6, 2026, its Board Compensation Committee granted inducement equity awards to eight new employees under the 2024 Inducement Plan. The grants include non-qualified stock options for 32,100 Class A shares at an exercise price of $40.13 and RSUs for 16,050 Class A shares, all vesting over four years, in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) announced a planned transition of the Chief Regulatory Officer role. William Turner will retire and become Strategic Advisor in Q3 after helping secure accelerated approval of TRUTAKNA for IgA nephropathy. Nancy Boman, M.D., Ph.D., a veteran regulatory leader with experience at Kyverna, Adicet Bio, Encoded Therapeutics, Novartis Gene Therapies, Amgen, Genentech, and Alder, will succeed him as Chief Regulatory Officer, supporting new indications for TRUTAKNA and other pipeline programs.
Vera Therapeutics (Nasdaq: VERA) received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. TRUTAKNA is a once-weekly 150 mg subcutaneous autoinjector that binds both BAFF and APRIL, targeting key immunological drivers of IgAN.
In the Phase 3 ORIGIN 3 interim analysis, TRUTAKNA achieved a 46% proteinuria reduction from baseline and 42% versus placebo at 36 weeks (p<0.0001), with generally well-tolerated safety. Continued approval may depend on confirming kidney function benefit, with eGFR results expected in Q3 2026.
Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards cover 28,800 stock options at a $31.26 exercise price and 14,150 RSUs for ten new employees, vesting over four years.
Vera Therapeutics (Nasdaq: VERA) announced U.S. FDA alignment on an earlier ORIGIN Phase 3 eGFR analysis for atacicept in adults with IgA nephropathy (IgAN).
The BLA for accelerated approval has a PDUFA date of July 7, 2026. eGFR results are expected in Q3 2026, supporting a planned sBLA in Q4 2026 and potential full approval in 2027.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted May 4, 2026 to ten new employees under its 2024 Inducement Plan. The Compensation Committee granted non-qualified stock options for 40,250 shares and RSUs underlying 20,125 shares.
Each option has an exercise price of $35.51 (closing price May 4, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest 25% annually beginning May 20, 2026. Awards are subject to the Inducement Plan and individual award agreements.